GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B7280 BMS CCR2 22Summary: CCR2 chemokine receptor antagonist
- B5333 SB 265610Summary: CXCR2 antagonist, potent
- B7508 NF 340Summary: P2Y11 antagonist
- B5344 DOB hydrochlorideSummary: Selective 5-HT2 receptor agonist
- B8010 NIBR189Summary: EBI2 (GPR183) receptor antagonist
- B8019 PimavanserinSummary: 5-HT2A inverse agonist
- B7783 TCS 3035Summary: GPR35 agonist
- B7792 AH 76141 CitationTarget: Free Fatty Acid ReceptorsSummary: FFA4/GPR120 antagonist
- B7793 GSK 137647Summary: FFA4/GPR120 agonist
- B4795 Labetalol HClSummary: A mixed α-/β-adrenergic antagonist